These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

623 related items for PubMed ID: 32624288

  • 1. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought.
    Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann KP, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A.
    Eur Urol; 2020 Nov; 78(5):661-669. PubMed ID: 32624288
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy.
    Bravi CA, Droghetti M, Fossati N, Gandaglia G, Suardi N, Mazzone E, Cucchiara V, Scuderi S, Barletta F, Schiavina R, Osmonov D, Juenemann KP, Boeri L, Karnes RJ, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Grubmüller B, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A.
    Eur Urol Oncol; 2022 Jun; 5(3):285-295. PubMed ID: 34176768
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series.
    Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann KP, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A.
    Eur Urol; 2020 Dec; 78(6):779-782. PubMed ID: 32624281
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Mid-term Outcomes Following Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Status Post-radical Prostatectomy.
    Zattoni F, Nehra A, Murphy CR, Rangel L, Mynderse L, Lowe V, Kwon E, Karnes RJ.
    Eur Urol Focus; 2016 Dec; 2(5):522-531. PubMed ID: 28723518
    [Abstract] [Full Text] [Related]

  • 9. Robotic salvage lymph node dissection for nodal-only recurrences after radical prostatectomy: Perioperative and early oncological outcomes.
    Linxweiler J, Saar M, Al-Kailani Z, Janssen M, Ezziddin S, Stöckle M, Siemer S, Ohlmann CH.
    Surg Oncol; 2018 Jun; 27(2):138-145. PubMed ID: 29937163
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficiency of repeat salvage lymph node dissection for recurrence of prostate cancer using PSMA-radioguided surgery (RGS) after prior salvage lymph node dissection with or without initial RGS support.
    Falkenbach F, Knipper S, Koehler D, Ambrosini F, Steuber T, Graefen M, Budäus L, Eiber M, Lunger L, Lischewski F, Heck MM, Maurer T.
    World J Urol; 2023 Sep; 41(9):2343-2350. PubMed ID: 37515651
    [Abstract] [Full Text] [Related]

  • 11. Oncological outcome of patients treated with spot-specific salvage lymphnode dissection (sLND) for positron-emission tomography (PET)-positive prostate cancer (PCa) relapse.
    Hiester A, Nini A, Niegisch G, Arsov C, Hautzel H, Antke C, Schimmöller L, Albers P, Rabenalt R.
    World J Urol; 2019 Oct; 37(10):2081-2090. PubMed ID: 30643974
    [Abstract] [Full Text] [Related]

  • 12. Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.
    Steuber T, Jilg C, Tennstedt P, De Bruycker A, Tilki D, Decaestecker K, Zilli T, Jereczek-Fossa BA, Wetterauer U, Grosu AL, Schultze-Seemann W, Heinzer H, Graefen M, Morlacco A, Karnes RJ, Ost P.
    Eur Urol Focus; 2019 Nov; 5(6):1007-1013. PubMed ID: 29530632
    [Abstract] [Full Text] [Related]

  • 13. Is 11C-choline Positron Emission Tomography/Computed Tomography Accurate to Detect Nodal Relapses of Prostate Cancer After Biochemical Recurrence? A Multicentric Study Based on Pathologic Confirmation from Salvage Lymphadenectomy.
    Oderda M, Joniau S, Palazzetti A, Falcone M, Melloni G, Van Den Bossche H, Deconinck S, Zattoni F, Karnes RJ, Gontero P.
    Eur Urol Focus; 2018 Mar; 4(2):288-293. PubMed ID: 30205893
    [Abstract] [Full Text] [Related]

  • 14. Combining PSA and PET features to select candidates for salvage lymph node dissection in recurrent prostate cancer.
    Bravi CA, Heidenreich A, Fossati N, Gandaglia G, Suardi N, Mazzone E, Stabile A, Cucchiara V, Osmonov D, Juenemann KP, Karnes RJ, Kretschmer A, Buchner A, Stief C, Hiester A, Albers P, Devos G, Joniau S, Van Poppel H, Grubmüller B, Shariat S, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A, Pfister D.
    BJUI Compass; 2023 Jan; 4(1):123-129. PubMed ID: 36569505
    [Abstract] [Full Text] [Related]

  • 15. Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review.
    Ploussard G, Gandaglia G, Borgmann H, de Visschere P, Heidegger I, Kretschmer A, Mathieu R, Surcel C, Tilki D, Tsaur I, Valerio M, van den Bergh R, Ost P, Briganti A, EAU-YAU Prostate Cancer Working Group.
    Eur Urol; 2019 Oct; 76(4):493-504. PubMed ID: 30391078
    [Abstract] [Full Text] [Related]

  • 16. Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience.
    Boeri L, Sharma V, Kwon E, Stish BJ, Davis BJ, Karnes RJ.
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):514-523. PubMed ID: 33268854
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Patterns of Clinical Recurrence of Node-positive Prostate Cancer and Impact on Long-term Survival.
    Nini A, Gandaglia G, Fossati N, Suardi N, Cucchiara V, Dell'Oglio P, Cazzaniga W, Luzzago S, Montorsi F, Briganti A.
    Eur Urol; 2015 Nov; 68(5):777-84. PubMed ID: 25959166
    [Abstract] [Full Text] [Related]

  • 19. Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy.
    Abdollah F, Briganti A, Montorsi F, Stenzl A, Stief C, Tombal B, Van Poppel H, Touijer K.
    Eur Urol; 2015 May; 67(5):839-49. PubMed ID: 24698524
    [Abstract] [Full Text] [Related]

  • 20. PSMA-positive nodal recurrence in prostate cancer : Salvage radiotherapy is superior to salvage lymph node dissection in retrospective analysis.
    Schmidt-Hegemann NS, Buchner A, Eze C, Rogowski P, Schaefer C, Ilhan H, Li M, Fendler WP, Bartenstein P, Ganswindt U, Stief C, Belka C, Kretschmer A.
    Strahlenther Onkol; 2020 Jul; 196(7):637-646. PubMed ID: 32211942
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.